Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 14 Oropharyngeal Neoplasms 12 Lung Neoplasms 12 Carcinoma, Non-Small-Cell Lung 10 Mouth Neoplasms 8 Laryngeal Neoplasms 8 Carcinoma 8 Small Cell Lung Carcinoma 7 Uterine Cervical Neoplasms 6 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 6 Nasopharyngeal Carcinoma 6 Mesothelioma, Malignant 6 Hypopharyngeal Neoplasms 6 Pancreatic Neoplasms 5 Triple Negative Breast Neoplasms 4 Medulloblastoma 4 Ganglioneuroblastoma 4 Gallbladder Neoplasms 4 Breast Neoplasms 4 Stomach Neoplasms 3 Salivary Gland Neoplasms 3 Prostatic Neoplasms 3 Neuroblastoma 3 Lymphoid Interstitial Pneumonia 3 Fallopian Tube Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Transitional Cell 3 Adenocarcinoma of Lung 3 Testicular Neoplasms 2

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Platinum × 1 year × Clear all

NCT07097948 2025-08-01

Adjuvant

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡